-
Sep 27, 2023, 09:06 AM
by
LIXTE Appoints Bas van der Baan as President and Chief Executive Officer
Full story
-
Sep 27, 2023, 09:06 AM
by
Cytel Inc. has acquired the Berlin-based company co.faktor GmbH.
Full story
-
Sep 27, 2023, 09:06 AM
by
Thirteen life science start-ups have been accepted onto Discovery Park’s new business support programme and competition, Discovery Spark. The eight-week Discovery Spark programme will equip the early-stage companies with the necessary skills to catalyse their business growth plans and gives them the chance to win a business support package worth over £100,000.
Full story
-
Sep 27, 2023, 01:00 AM
by
User Not Found
Bio-IT World| Moderna and Immatics launch a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high unmet medical need; The National Institutes of Health is establishing the Multi-Omics for Health and Disease Consortium to advance the generation and analysis of “multi-omic” data for human health research; Generate:Biomedicines has secured huge funding to advance its AI platform used to increase precision, speed, and probability of success of novel therapeutics; more.
Full story
-
Sep 26, 2023, 09:29 AM
by
Full story
-
Sep 26, 2023, 01:00 AM
by
User Not Found
Bio-IT World| As artificial intelligence continues to rapidly develop, it is tempting for organizations to rush into using AI—or at least an AI buzzword. In the latest episode of the Trends from the Trenches podcast, host Stan Gloss channels Simon Sinek and challenges Bryn Roberts to start with why.
Full story
-
Sep 25, 2023, 18:53 PM
by
Optibrium, a leading developer of software and AI solutions for drug discovery, today launched the latest version of its drug discovery platform, StarDrop 7.5, introducing a powerful module for drug metabolism prediction.
Full story
-
Sep 25, 2023, 18:53 PM
by
Bio-IT World Europe will convene in London 29-30 November 2023 to foster collaboration among the UK and Europe's biopharma and technology leaders who are forging new frontiers in precision medicine.
Full story
-
Sep 25, 2023, 08:55 AM
by
Full story
-
Sep 25, 2023, 08:55 AM
by
Full story
-
Sep 25, 2023, 08:55 AM
by
Full story
-
Sep 25, 2023, 08:55 AM
by
Full story
-
Sep 25, 2023, 08:55 AM
by
Full story
-
Sep 25, 2023, 08:55 AM
by
MAVERICK is a Raman-based PAT solution that requires no complex modeling. It is an optical in-line analyzer that provides real-time monitoring and control of glucose, lactate, and total biomass in mammalian cell cultures, in addition to rich process fingerprint data to support large-scale efforts in predictive bioprocess modeling. MAVERICK is also the first turn-key device to utilize Raman spectroscopy for bioprocess control, with no modeling and development required. With its in-line optical sampling probe, biopharmaceutical scientists and engineers can quickly develop their cell culture media and design feeding and control strategies.
Full story
-
Sep 22, 2023, 08:33 AM
by
Mirikizumab is the first IL-23p19 targeted biologic recommended by NICE for use within NHS England and Wales for treating moderately to severely active ulcerative colitis in adults.1,2.
In two randomised, double-blind, placebo-controlled phase 3 trials, LUCENT-1 and LUCENT-2, mirikizumab achieved primary and key secondary endpoints, including sustained clinical remission. Decreases in bowel urgency severity were observed as early as week 2 in patients treated with mirikizumab versus placebo in LUCENT-1.2
Mirikizumab has been recommended through the NICE cost-comparison process meaning NHS England and commissioning groups have agreed to provide funding to implement this guidance within 30 days from publication of the technology appraisal guidance (TAG) rather than the standard 90 days, providing faster access to a new treatment option for eligible adults living with moderately to severely active ulcerative colitis1
Full story
-
Sep 22, 2023, 08:33 AM
by
Full story
-
Sep 22, 2023, 08:33 AM
by
Full story
-
Sep 22, 2023, 08:33 AM
by
Full story
-
Sep 22, 2023, 08:33 AM
by
Health Plan of San Joaquin (HPSJ) just announced they selected ZeOmega’s care management solution to support the complex health needs of 450,000+ Medi-Cal members and promote equitable care statewide.
HPSJ will use ZeOmega’s platform to consolidate and analyze members’ health data to produce insights informing care needs. The partnership will empower HPSJ to support members’ physical, mental, and behavioral health needs and align with CalAIM’s whole-person approach to healthcare.
Full story
-
Sep 21, 2023, 08:26 AM
by
Kalderos names veteran healthcare leader Angie Franks as new CEO
Full story